

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		To be assigned	
				FILING DATE		Concurrently herewith	
				APPLICANT		Keith Biggadike et al.	
				GROUP		To be assigned	
				EXAMINER		To be assigned	
				ATTORNEY DOCKET NO.		PB60390USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
BB	1.	3,856,828	12/24/1974	PHILLIPPS et al.	—	—	
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
BB	2.	GB 1384372	02/19/1975	GB	—	—	
	3.	GB 1514476	06/14/1978	GB	—	—	
	4.	GB 2079755	01/27/1982	GB	—	—	
	5.	GB 2137206	10/03/1984	GB	—	—	
	6.	WO 89/03390	04/20/1989	PCT	—	—	
BB	7.	WO 02/00679	01/03/2002	PCT	—	—	
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
BB	8.	Ueno et al., "Synthesis and evaluation of anti-inflammatory activities of a series of corticosteroid 17.alpha.-esters containing a functional group," <i>Journal of Medicinal Chemistry</i> 34(8):2468-2473 (Aug. 1991).					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
/Barbara Badio/					03/08/2007		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	10/564,325
	FILING DATE	May 17, 2006
	APPLICANT	Keith Biggadike et al.
	GROUP	1617
	EXAMINER	Badio, Barbara P
ATTORNEY DOCKET NO.		PB60390USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
BB	1.	5,552,438	09/03/1996	CHRISTENSEN, IV			
	2.	6,172,054	01/09/2001	CLARK			
	3.	6,245,804	06/12/2001	LEHMANN et al.			
	4.	6,395,738	05/28/2002	OHSHIMA et al.			
BB	5.	6,897,224	05/24/2005	JAROCH et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
BB	6.	WO 93/13055	07/08/1993	PCT			
	7.	WO 95/34534	12/21/1995	PCT			
	8.	WO 97/41867	11/13/1997	PCT			
	9.	WO 98/30537	07/16/1998	PCT			
	10.	WO 98/54159	12/03/1998	PCT			X
	11.	WO 99/16766	04/08/1999	PCT			X
	12.	WO 99/32127	07/01/1999	PCT			
	13.	WO 99/47505	09/23/1999	PCT			
	14.	WO 99/62875	12/09/1999	PCT			
	15.	WO 00/66590	11/09/2000	PCT			
	16.	WO 01/04118	01/18/2001	PCT			
	17.	WO 01/10143	02/08/2001	PCT			
	18.	WO 01/16128	03/08/2001	PCT			
	19.	WO 01/42193	06/14/2001	PCT			
	20.	WO 02/02565	01/10/2002	PCT			
	21.	WO 02/26722	04/04/2002	PCT			
	22.	WO 02/40030	05/23/2002	PCT			
	23.	WO 02/50021	06/27/2002	PCT			
	24.	WO 02/66422	08/29/2002	PCT			
	25.	WO 02/70490	09/12/2002	PCT			
	26.	WO 02/76933	10/03/2002	PCT			
	27.	WO 03/08277	01/30/2003	PCT			
	28.	WO 03/024439	03/27/2003	PCT			
	29.	WO 03/042160	05/23/2003	PCT			
BB	30.	WO 03/059899	07/24/2003	PCT			

Continue on page 2

EXAMINER

/Barbara Badio/

DATE CONSIDERED
03/08/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT						SERIAL NO.	10/564,325		
						FILING DATE	May 17, 2006		
						APPLICANT	Keith Biggadike et al.		
						GROUP	1617		
						EXAMINER	Badio, Barbara P		
						ATTORNEY DOCKET NO.	PB60390USw		
FOREIGN PATENT DOCUMENTS (Cont'd)									
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No		
BB	31.	WO 03/061651	07/31/2003	PCT					
	32.	WO 03/072539	09/04/2003	PCT					
	33.	WO 03/082280	10/09/2003	PCT					
	34.	WO 03/082787	10/09/2003	PCT					
	35.	WO 03/082827	10/09/2003	PCT			X		
	36.	WO 03/086294	10/23/2003	PCT					
	37.	WO 03/091204	11/06/2003	PCT					
	38.	WO 03/101932	12/11/2003	PCT					
	39.	WO 03/104195	12/18/2003	PCT					
	40.	WO 04/005229	01/15/2004	PCT					
	41.	WO 04/009016	01/29/2004	PCT					
	42.	WO 04/009017	01/29/2004	PCT					
	43.	WO 04/016578	02/26/2004	PCT					
	44.	WO 04/018429	03/04/2004	PCT					
	45.	WO 04/022547	03/18/2004	PCT					
	46.	WO 04/024728	03/25/2004	PCT					
	47.	WO 04/026248	04/01/2004	PCT					
	48.	WO 04/037768	05/06/2004	PCT					
	49.	WO 04/037773	05/06/2004	PCT					
	50.	WO 04/037807	05/06/2004	PCT					
	51.	WO 04/039762	05/13/2004	PCT					
↓	52.	WO 04/039766	05/13/2004	PCT					
BB	53.	WO 04/056823	07/08/2004	PCT					
	54.	WO 04/103998	12/02/2004	PCT					
Continue on page _____									
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
BB	55.	Austin et al., "Mometasone furoate is a less specific glucocorticoid than fluticasone propionate," <i>Eur Resp J</i> . 20(6):1386-1392 (Dec. 2002).							
	56.	Fuji et al., "Novel phosphodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen," <i>J Pharmacol Exp Ther</i> 284(1):162 (1998).							
	57.	Landells et al., "Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex-vivo agonist-induced-cell activation," <i>Eur Resp J (Annu Cong Eur Resp Soc, Geneva)</i> 12(Suppl. 28) Abst P2393 (Sep. 1998).							
	58.	Phillipps et al., "Synthesis and Structure-Activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17 β -carbothioates and -17 β -carbosenoates," <i>J. Med. Chem.</i> 37(22):3717-3729 (1994).							
↓	59.	RACHWAL et al., "Chemistry of Ioteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compounds," <i>Steroids</i> 63 (4):193-201 (1998)							
BB	60.	Ray et al., "Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor α , and inhibition by glucocorticoids," <i>Biochem J</i> . 328:707-715 (Dec. 1997).							
Continue on page _____									
EXAMINER /Barbara Badio/					DATE CONSIDERED 03/08/2007				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.									